A Phase 3 interventional study of ACP-204 in Alzheimer's Disease Psychosis, sponsored by ACADIA Pharmaceuticals Inc.. Enrolling by invitation at 78 sites in 12 countries. Open to participants aged 55 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by ACADIA Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Hallucinations with a site in United States — 11 open to participants now, 11 under way, 2 of them phase 3. Hallucinations · United States.
Among the 51 studies in Hallucinations with a site in United States, this one is the 2nd largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 3, reaches primary completion later than 7 of the 10 other live ones, and was the 45th registered.
137 studies on the registry are indexed under Hallucinations; 36 are open to participants now.
Browse Hallucinations studies →11 of the 51 studies in Hallucinations with a site in United States are open now. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18–90 · Healthy volunteers
MapLight Therapeutics · Sites in United States, Argentina, Bulgaria and 12 more countries
Ages 55–90
ACADIA Pharmaceuticals Inc. · Sites in United States, Brazil, Bulgaria and 9 more countries
Ages 55–95
The University of Texas Health Science Center at San Antonio · Sites in United States
Boston VA Research Institute, Inc. · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Hallucinations studies recruiting now, 8 (35%) set no upper age limit and 11 (48%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 55 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 4 · Phase 4 2
First in 1995; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 752 is above the median of 46 across 119 interventional studies indexed under Hallucinations.
Median enrollment 35 across the 47 interventional studies, 144 across the 4 observational. Of the 38 that completed or were terminated, 19 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 51 have an industry lead sponsor. The 10 most frequent:
ACADIA Pharmaceuticals Inc. is the lead sponsor of 41 studies on the registry; 5 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 24 (92%) have results posted.
ACADIA Pharmaceuticals Inc. has 5 studies filed under Hallucinations — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 51 studies in Hallucinations with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACP-204 30mg or 60mg
Drug: ACP-204
ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
Treatment-emergent adverse events
Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) over 52 weeks of treatment. The Safety population consists of all subjects who received at least one dose of study drug in this study.
Time frame: 52 Weeks
Clinical Global Impression-Improvement in the ADP context (CGI-I-ADP) score
Time frame: 52 Weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Apr 2029, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remlifanserin